




**Oman Neurology Society (ONS)
and Oman Epilepsy Society (OES)**

In collaboration with

Medicine Department, Nizwa Hospital



**2nd Oman Neurology
Conference**

- **Date:** Friday, 27th May 2022
- **Venue:** Inter City Hotel, Nizwa
- **Registration is Free**




For registration:

PD&CG Dept. Nizwa Hospital: 25211090 / 25211651



حضرة صاحب الجلالة
السلطان هيثم بن طارق المعظم



المغفور له
السلطان قابوس بن سعيد -طيب الله ثراه-

Warm Greetings, esteemed attendees,

It is a great pleasure and honor to welcome you to the 2nd Oman Neurology Conference. While we regret that the COVID pandemic prevented us from holding the conference on 11th February 2022, we are excited about the opportunity of having it on 27th May 2022 in the Intercity Hotel in Nizwa.

The event is organized by the Oman Neurology Society (ONS) and Oman Epilepsy Society (OES) in collaboration with the Medicine Department of Nizwa Hospital.

The conference will present scientific knowledge on epilepsy, Headaches, CNS demyelination, and other common neurological disorders relevant to the medical professional dealing with patients with neurological disorders.

We like to thank the sponsoring pharmaceutical companies and all the support we received from the Nizwa hospital administration.

It is a privilege to hold the conference in Nizwa city. There are many tourist attractions in the city and its surroundings, including but not limited to the Nizwa fort, the traditional Souq, the "Al-A'qr" area, and Falaj Daris.

We like you to enjoy the scientific component of the conference and have the chance to visit Nizwa and its surrounding areas.

Thank you again for your presence and participation.

Oman Neurology Society (ONS) Board Members (2021-2023)

- Dr. Abdullah Al-Salti President
- Dr. Amna Al-Futaisi Vice President
- Dr. Ahmed Al-Qassabi Secretary
- Dr. Abdullah Al-Asmi Treasurer
- Prof Arunodaya Gujjar Member
- Dr. Abdullah AL-Jamal Member
- Dr. Ahmed Sameer Member

Oman Epilepsy Society (OES) and Oman League Against Epilepsy Board Members (2021-2023)

- Dr. Amna Al-Futaisi President
- Dr. Talal Al-Mashaikhi 1st Vice President
- Dr. Haifa Al-Abri Secretary
- Dr. Abdullah Al-Asmi Treasurer
- Dr. Wafa Al-Shihi 2nd Vice President
- Dr. Bosanka Jovic-Jakubi Member

Scientific and Organizing Committee

- Dr. Abdullah Al-Asmi Chairman
- Dr. Abdullah Al-Salti
- Dr. Ahmed Al-Qassabi
- Prof Arunodaya Gujjar
- Dr. Ahmed Sameer
- Dr. Jaber K. Alkhaboori
- Dr. Saif Al-Adawi
- Dr. Abdullah Al-Subhi
- Dr Ali Aamini
- Salim Abdullah Alburtamani
- Sausan Saif Alrahbi
- Fadheel Fadhil Alhadadi.
- Mis. Umaima Al-Subhi

Second Oman Neurology Conference

(Organized by ONS/OES in collaboration with Nizwa hospital)

Program in glance

Time	Title	Presenter
7:30-8:15	Registration	
8:15-8:20	Opening Remarks	Dr. Abdullah Al-Asmi, Chairman, Organizing Committee
8:20-12:00	First Session: Headache/Epilepsy	
13:20-15:15	Second Session: Multiple Sclerosis	
15:35-17:15	Third Session: Other Neurological Disorders	
17:15-17:20	Closing remarks	Dr. Abdullah Al-Salti, president ONS

Second Oman Neurology Conference

(organized by ONS/OES in collaboration with Nizwa hospital)

Program Details:

Time	Title	Presenter
7:30-8:15	Registration	
8:15-8:20	Opening Remarks	Dr. Abdullah Al-Asmi, Chairman, Organizing Committee
First Session: Headache/Epilepsy		
	Moderator: Dr. Abdelhamid R Seiam and Dr. Sulaiman Al-Hatmi	
8:20-8:40	Approach to headache in Children	Dr Nabil Al Macki
8:40-9:00	Primary headaches in adults	Dr. Saif Al-Adawi
9:00-9:20	Approach to paroxysmal events in adults	Dr. Haifa Al-Abri
9:20-9:40	Paroxysmal non-epileptic disorders in Children	Dr. Bosanka Jovic-Jakubi
9:40-10:00	Drug-Resistant Epilepsy	Dr. Haifa Al-Abri
10:00-10:15	Questions and Answers	All Speakers of the session
10:15-10:40	Break	
10:40-11:00	Satellite symposium Novartis "The Next Generation in B-Cell-Targeted Therapies"	Professor Bassem Yamout
11:00-11:20	Satellite symposium GSK "Management of Women with Epilepsy"	Prof. Arunodaya R Gujjar
11:20-11:40	Satellite symposium Biogen "Understanding SMA in Children and Adults: From diagnosis to management"	Dr Nabil Al Macki
11:40-12:00	Satellite symposium Novartis "Local RWE on Erenumab"	Dr. Deeb Kayed
12:00-13:20	Prayer and Lunch Break	

Second Session: Multiple Sclerosis

Moderators: Dr. Ahmed Sameer and Dr. Abdullah AlJamal

13:20-13:40	Acute Demyelinating Disorders in Children	Dr. Faraz Ahamad
13:40-14:00	Diagnostic Criteria for Demyelinating disorders (MS/NMO)	Dr. Jaber Khabouri
14:00-14:20	Management of MS relapse and managing MS specific therapies for MS patients	Dr. Abdullah Al-Asmi
14:20-14:40	Satellite symposium-Sanofi-Genzyme "Going Beyond Acute Inflammation in Managing Patients with RRMS"	Dr. Jaber Khabouri
14:40-15:00	Satellite symposium Biogen "Shaping Clinical Practice from Trial Data: 13 Years of TECFIDERA® (dimethyl fumarate)"	Dr. Abdullah Al-Asmi
15:00-15:15	Questions and Answers	
15:15-15:35	Break	

Third Session: Other Neurological Disorders

Moderators: Prof. Khaleel Al-Shaikhly and Dr. Ahmed Mansy

15:35-15:55	Hereditary myopathies in Oman	Dr. Abdullah Al-Salti
15:55-16:15	Common Movement Disorders in general practice	Dr. Ahmed Al-Qassabi
16:15-16:35	Cerebrovascular complications of COVID-19	Dr. Ali Al-Balushi
16:35-16:55	Satellite symposium-Sanofi-Genzyme "Neuromuscular Disorders: a treatable condition?"	Dr. Abdullah Al-Salti
16:55-17:15	Questions and Answers	All Speakers of the session
17:15-17:20	Closing remarks	Dr. Abdullah Al-Salti, president ONS

SESSION MODERATORS



Dr. Abdelhamid R Seiam, MSc, PhD, CSCN

Associate Professor of Neurology, Cairo, Egypt
Consultant Neurologist, Epileptologist, Khoula Hospital,
Muscat, Oman



**Dr Sulaiman Al Hatmi, MD, OMSB MRCP (Neurology), FRCPI
(general Neurology), FRCPI (epilepsy),**

Consultant Neurologist,
Head of Neurology division, Medicine Department,
Armed Force Hospital (AFH).



Dr. Ahmed Sameer Mahmud Nadeem, MBChB MD, MSc, PhD

Associate Professor of Neurophysiology
Consultant Clinical Neurophysiologist
Neurology Department, Khoula Hospital
MOH, Muscat-Oman



Dr. Abdulla K. Al Jamal MD, MBChB, FIBMS(Neuro)

Senior Neurologist, Head of Neurology Department
Badr Al Samaa Hospital -Al Khoud ,Muscat, Oman
Board Member, Oman Neurology Society



Khaleel AlShaikhli (MRCP, UK, FRCP,G)

Professor of neurology, senior consultant neurologist
khoula hospital, MOH, Oman



Dr. Ahmed A. Mansy, MD, M.Sc., PhD.

Senior Consultant Pediatric Neurologist,
Child Health Department, SQUH
Senior Lecturer of Pediatrics and Pediatric Neurology, Children
hospital, Cairo University



SPEAKERS





Dr Nabil Al Macki MD,DCH,MRCPCH,FRCP-C

Head of pediatric Neurology, Royal hospital
Muscat, Oman



Dr. Saif Al-Adawi, BSc, MD, OMSB, MRCP, RCP-Neuro

Consultant Neurologist, Stroke specialist and internist
Daris Medical Center, Nizwa



Dr. Haifa Al-Abri, MD, ABPN

Consultant Neurologist and Epileptologist,
SQUH
OLAE/OES Secretary



Dr Bosanka Jovic-Jakubi, MD.Ph.D.,

Pediatric Neurologist & Epileptologist
CHD, SQUH, Muscat Oman,
Department of Child Neurology, Clinical Center Nis, Serbia
Trainer of European Epilepsy Academy (EUREPA)
Board Member of OLAE
Member of ILAE Telemedicine Task Force
Expert in the c4c Neuroscience & Epilepsy Expert Group



Prof. Bassem Yamout

Professor of Neurology, American University of Beirut,
President of MENACTRIMS
Director, Neurology Institute, Harley Street Medical Center Head,
MS Center, Harley Street MC-Abu Dhabi
Abu Dhabi, UAE



Prof. Arunodaya R Gujjar DM, FRCP

Professor of Neurology,
Dept of Medicine (Neurology unit),
COMHS and SQUH, SQU
Muscat, Oman



Dr. Deeb M Kayed

US Board Certified Neurologist and Clinical Neurophysiologist.
Consultant Neurologist in Private Practice at IRAC with admission
privileges at Mediclinic City Hospital and American Hospital,
Dubai, UAE.

Assistant Professor of Neurology at Mohamed Bin Rashid
University School of Medicine, Dubai, UAE.



Dr Faraz Ahmad, MBBS, MD, MRCPCH

Clinical Fellowship Pediatric Neurology, UK
Pediatric Neurologist
Department of Child Health
SQUH, Muscat, Oman



Dr. Jaber K. Alkhaboori, MD, MRCP, FTTA London

Senior consultant neurologist
Head Of MS Care Team
Khoulā Hospital
Muscat, Oman



Dr. Abdullah Al-Asmi, MD, FRCPC

Associate Professor and Senior Consultant Neurologist
COMHS/SQUH, SQU, Muscat, Oman
Treasurer Oman Neurology and Epilepsy Societies



Dr. Abdullah Mohammed Al-Salti ,MD,MECP(UK),FRCPC, CSCN
Senior Consultant Neurologist, Neuromuscular and EMG specialist
Head of the Neurology department at Neuroscience Center
Khoula Hospital Muscat
Muscat, Oman



Dr. Ahmed Al-Qassabi MD, FRCPC
Consultant in Neurology and Movement disorders Specialist
Sultan Qaboos University Hospital
Secretary of Oman Neurology Society



Dr. Ali Al Balushi, MD, MRCP (UK)

Diplomate of the ABPN in Neurology & Vascular Neurology
Consultant, Vascular Neurologist and Neurointerventionalist
Department of Neurology
Khoulā Hospital, Muscat, Oman

Nizwa Hospital

Nizwa Hospital was opened on 02.09.1971 by his majesty Qaboos bin Said, the late Sultan of Oman. It was rebuilt and reopened on Wednesday, the thirtieth of September 1998, to be a reference hospital to provide secondary health care for the population of the province of Al Dakhlya and its neighboring regions. The hospital has 309 beds. It also contains the accident and emergency, delivery rooms, dialysis unit, and maternity care. A well-equipped laboratory and radiology departments support the diagnostic services in the hospital.

Over the last few years, new services have been introduced to the hospital, including neurology, neurosurgery, and stroke unit.

Nizwa hospital will soon open one of its major development projects. This will increase the bed capacity to more than 500 beds and will introduce new services such as MRI, cardiac catheterization, and daycare.

SPONSORS



*THIS INCLUDES CLINICAL TRIAL USE AND PATIENTS PRESCRIBED TECFIDERA.

FOR THE TREATMENT OF ADULT
PATIENTS WITH RRMS

***START EARLY.
STAY IN CONTROL.***

TECFIDERA effectively impacts disease
activity in the long term.¹⁻⁵



Biogen-131285 | January 2022

References:

1. TECFIDERA SmPC; please refer to the approved SmPC in your country. 2. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. *J Neurol*. 2017;264(12):2351-2374. 3. Gold R, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. *Mult Scler*. 2017;23(2):253-265. 4. Gold R, et al. Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 8-year interim results from an extension of the DEFINE and CONFIRM studies. *Neurol Ther*. 2016;5:45-57. 5. Tecfidera Exposure Data 4 March 2021. Biogen Data on File.

LONG-TERM REAL-WORLD EXPERIENCE WITH TYSABRI¹



**THE POWER YOU NEED
THE EXPERIENCE YOU TRUST**
FOR YOUR HIGHLY ACTIVE RRMS PATIENTS

230,000+
patients treated
with TYSABRI
globally*¹

>920,000
patient-years
of exposure*¹



References: ¹. Biogen, data on file: Global Natalizumab (TYSABRI) Postmarketing PML Update. July 2021.

* Biogen data on file, as of July 2021.

© 2021 Biogen. All rights reserved, Biogen-149684. Date of preparation: December 2021.







Kesimpta™

(ofatumumab) 20mg/0.4ml
Solution for injection



MAYZENT®

siponimod

Living with RRMS can feel like a storm

Count on the consistent efficacy and safety of AUBAGIO® to calm the storm^{1-5*}

A large, dark, textured image, possibly a close-up of a rock surface or a heavily textured wall, with a grid of small, light-colored squares overlaid on the right side. The texture is rough and uneven, with various shades of gray and black. The grid consists of small, light-colored squares arranged in a regular pattern, covering the right half of the image. The overall appearance is that of a high-contrast, black and white photograph of a natural surface.

SANOFI GENZYME 

For further information, please contact: David Thompson
Director, Planning, Health & Environmental Services Unit, 2000, PO Box 2288, St John's, NL A1B 4X6
Tel: (709) 576-4111 ext. 2222 Fax: (709) 576-4111
E-mail: david.thompson@health.nfld.ca

Once-daily

AUBAGIO®
(teriflunomide) 14 mg
tablets

AAO 48-170000-0000

LEMTRADA's impact is measured by her meaningful moments

LEMTRADA's impact is measured by her meaningful moments

Lamivudine treatment should only be initiated and supervised by a neurologist experienced in the treatment of patients with multiple sclerosis in a hospital with ready access to intensive care. Specialists and equipment required for the timely diagnosis and management of adverse reactions, especially myocardial ischaemia and myocardial infarction, cerebrovascular adverse reactions, autoimmune conditions, and infections should be available. Samtini is in process to update the leaflet in EU countries as per the above EC decision.

[illegible][illegible]

For further medical information, please contact: For UAE 800 MEDICAL Toll Free Number, for all Gulf Countries +971 565776791 or email: medical-information.gulf@sanofi.com full prescribing information is available upon request.
To Report adverse events please call: +971 561747001 or email: Gulf.Pharmacovigilance@sanofi.com

MANUSCRIPT RECEIVED 15 FEBRUARY 1987

LEMTRADA®
alemtuzumab 12mg/IV

